Search
Now showing items 1-10 of 56
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer
(1997)
We performed a phase II study to evaluate the activity and toxicity of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin as first-line treatment in patients with recurrent ...
Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the hellenic cooperative oncology group
(1997)
37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg · min/ml every 4 weeks with G-CSF support. There ...
Phase II clinical trials with rhizoxin in breast cancer and melanoma
(1996)
Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose ...
Effect of intravenous nitroglycerin on lipid peroxidation after thrombolytic therapy for acute myocardial infarction
(1998)
Free oxygen radicals are produced after coronary artery occlusion and reperfusion. Polyunsaturated fatty acids are oxidized by free radicals to lipid peroxides. Measurements of plasma malondialdehyde (MDA) formed by the ...
Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer: A hellenic co-operative oncology group study
(1994)
Purpose: To compare the efficacy and toxicity of etoposide and cisplatin (EP) with etoposide and carboplatin (EC) in combination with irradiation in small-cell lung cancer (SCLC). Methods: Previously untreated patients ...
Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-operative Oncology Group phase II study
(1998)
The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this ...
Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes
(1998)
Forty-one patients with operable breast cancer and ≥ 10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A ...
Effect of pentoxifylline on treatment of lower limb ulcers in patients with thalassemia major
(1992)
The possible healing effect of deferoxamine and pentoxifylline on persisting lower limb ulcers was studied in 51 patients with thalassemia major. The results indicated that the regular use of deferoxamine at an intravenous ...
Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients
(1996)
A total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15-3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and ...